^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
luxdegalutamide (ARV-766)
i
Other names: ARV-766, ARV 766, ARV766, JSB 462, JSB462, JSB-462
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Arvinas, Novartis
Drug class:
Androgen receptor degrader, AR-V7 degrader
Related drugs:
21h
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
P2, N=138, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Nov 2028 --> May 2028 | Trial primary completion date: Jan 2028 --> Jul 2027
Trial completion date • Trial primary completion date
|
Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • luxdegalutamide (ARV-766)
8d
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01) (clinicaltrials.gov)
P1/2, N=188, Recruiting, Novartis Pharmaceuticals
Trial initiation date
|
tulmimetostat (DZR123) • luxdegalutamide (ARV-766)
14d
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
P2, N=134, Active, not recruiting, Novartis Pharmaceuticals
Trial initiation date
|
Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • luxdegalutamide (ARV-766)
21d
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
P2, N=130, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting
Enrollment closed
|
Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • luxdegalutamide (ARV-766)
2ms
CDZR123A12107: A clinical trial to learn about the effects of DZR123 and JSB462 given together in men with advanced prostate cancer that has stopped responding to other treatments (2025-521880-10-00)
P1/2, N=76, Recruiting, Novartis Pharma AG | Not yet recruiting --> Recruiting
Enrollment open
|
docetaxel • Xtandi (enzalutamide) • abiraterone acetate • cabazitaxel • tulmimetostat (DZR123) • luxdegalutamide (ARV-766)
2ms
CJSB462B12201: A Phase II, randomized, open-label, multi-center study of JSB462 (luxdegalutamide) in combination with lutetium (177Lu) vipivotide tetraxetan in adult male patients with PSMA-positive metastatic castration resistant prostate cancer (mCRPC) (2024-520155-24-00)
P1/2, N=46, Recruiting, Novartis Pharma AG
New P1/2 trial
|
Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • luxdegalutamide (ARV-766)
2ms
CDZR123A12107: A clinical trial to learn about the effects of DZR123 and JSB462 given together in men with advanced prostate cancer that has stopped responding to other treatments (2025-521880-10-00)
P1/2, N=76, Not yet recruiting, Novartis Pharma AG
New P1/2 trial
|
docetaxel • Xtandi (enzalutamide) • abiraterone acetate • cabazitaxel • tulmimetostat (DZR123) • luxdegalutamide (ARV-766)
3ms
A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate Cancer (clinicaltrials.gov)
P1, N=15, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
Enrollment open
|
luxdegalutamide (ARV-766)
7ms
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01) (clinicaltrials.gov)
P1/2, N=188, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
Enrollment open
|
tulmimetostat (DZR123) • luxdegalutamide (ARV-766)
7ms
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01) (clinicaltrials.gov)
P1/2, N=188, Not yet recruiting, Novartis Pharmaceuticals
New P1/2 trial
|
tulmimetostat (DZR123) • luxdegalutamide (ARV-766)
7ms
A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate Cancer (clinicaltrials.gov)
P1, N=15, Not yet recruiting, Novartis Pharmaceuticals
New P1 trial
|
luxdegalutamide (ARV-766)
10ms
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
P2, N=130, Recruiting, Novartis Pharmaceuticals
New P2 trial
|
Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • luxdegalutamide (ARV-766)
Share via
